Mitochondria-targeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease

Marcus J. Calkins, Maria Manczak, P (Hemachandra) Reddy

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    In neuronal systems, the health and activity of mitochondria and synapses are tightly coupled. For this reason, it has been postulated that mitochondrial abnormalities may, at least in part, drive neurodegeneration in conditions such as Alzheimer's disease (AD). Mounting evidence from multiple Alzheimer's disease cell and mouse models and postmortem brains suggest that loss of mitochondrial integrity may be a key factor that mediates synaptic loss. Therefore, the prevention or rescue of mitochondrial dysfunction may help delay or altogether prevent AD-associated neurodegeneration. Since mitochondrial health is heavily dependent on antioxidant defenses, researchers have begun to explore the use of mitochondria-targeted antioxidants as therapeutic tools to prevent neurodegenerative diseases. This review will highlight advances made using a model mitochondria-targeted antioxidant peptide, SS31, as a potential treatment for AD.

    Original languageEnglish (US)
    Pages (from-to)1103-1119
    Number of pages17
    JournalPharmaceuticals
    Volume5
    Issue number10
    DOIs
    StatePublished - Oct 16 2012

    Fingerprint

    Amyloid
    Alzheimer Disease
    Mitochondria
    Antioxidants
    Health
    Neurodegenerative Diseases
    Synapses
    Research Personnel
    Brain
    Therapeutics

    Keywords

    • Alzheimer's
    • Antioxidant
    • Mitochondria
    • SS31

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmaceutical Science

    Cite this

    Mitochondria-targeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. / Calkins, Marcus J.; Manczak, Maria; Reddy, P (Hemachandra).

    In: Pharmaceuticals, Vol. 5, No. 10, 16.10.2012, p. 1103-1119.

    Research output: Contribution to journalArticle

    Calkins, Marcus J. ; Manczak, Maria ; Reddy, P (Hemachandra). / Mitochondria-targeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. In: Pharmaceuticals. 2012 ; Vol. 5, No. 10. pp. 1103-1119.
    @article{e1f5dfb6be144d6abf21c0bd1c3a142d,
    title = "Mitochondria-targeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease",
    abstract = "In neuronal systems, the health and activity of mitochondria and synapses are tightly coupled. For this reason, it has been postulated that mitochondrial abnormalities may, at least in part, drive neurodegeneration in conditions such as Alzheimer's disease (AD). Mounting evidence from multiple Alzheimer's disease cell and mouse models and postmortem brains suggest that loss of mitochondrial integrity may be a key factor that mediates synaptic loss. Therefore, the prevention or rescue of mitochondrial dysfunction may help delay or altogether prevent AD-associated neurodegeneration. Since mitochondrial health is heavily dependent on antioxidant defenses, researchers have begun to explore the use of mitochondria-targeted antioxidants as therapeutic tools to prevent neurodegenerative diseases. This review will highlight advances made using a model mitochondria-targeted antioxidant peptide, SS31, as a potential treatment for AD.",
    keywords = "Alzheimer's, Antioxidant, Mitochondria, SS31",
    author = "Calkins, {Marcus J.} and Maria Manczak and Reddy, {P (Hemachandra)}",
    year = "2012",
    month = "10",
    day = "16",
    doi = "10.3390/ph5101103",
    language = "English (US)",
    volume = "5",
    pages = "1103--1119",
    journal = "Pharmaceuticals",
    issn = "1424-8247",
    publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
    number = "10",

    }

    TY - JOUR

    T1 - Mitochondria-targeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease

    AU - Calkins, Marcus J.

    AU - Manczak, Maria

    AU - Reddy, P (Hemachandra)

    PY - 2012/10/16

    Y1 - 2012/10/16

    N2 - In neuronal systems, the health and activity of mitochondria and synapses are tightly coupled. For this reason, it has been postulated that mitochondrial abnormalities may, at least in part, drive neurodegeneration in conditions such as Alzheimer's disease (AD). Mounting evidence from multiple Alzheimer's disease cell and mouse models and postmortem brains suggest that loss of mitochondrial integrity may be a key factor that mediates synaptic loss. Therefore, the prevention or rescue of mitochondrial dysfunction may help delay or altogether prevent AD-associated neurodegeneration. Since mitochondrial health is heavily dependent on antioxidant defenses, researchers have begun to explore the use of mitochondria-targeted antioxidants as therapeutic tools to prevent neurodegenerative diseases. This review will highlight advances made using a model mitochondria-targeted antioxidant peptide, SS31, as a potential treatment for AD.

    AB - In neuronal systems, the health and activity of mitochondria and synapses are tightly coupled. For this reason, it has been postulated that mitochondrial abnormalities may, at least in part, drive neurodegeneration in conditions such as Alzheimer's disease (AD). Mounting evidence from multiple Alzheimer's disease cell and mouse models and postmortem brains suggest that loss of mitochondrial integrity may be a key factor that mediates synaptic loss. Therefore, the prevention or rescue of mitochondrial dysfunction may help delay or altogether prevent AD-associated neurodegeneration. Since mitochondrial health is heavily dependent on antioxidant defenses, researchers have begun to explore the use of mitochondria-targeted antioxidants as therapeutic tools to prevent neurodegenerative diseases. This review will highlight advances made using a model mitochondria-targeted antioxidant peptide, SS31, as a potential treatment for AD.

    KW - Alzheimer's

    KW - Antioxidant

    KW - Mitochondria

    KW - SS31

    UR - http://www.scopus.com/inward/record.url?scp=84869231972&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84869231972&partnerID=8YFLogxK

    U2 - 10.3390/ph5101103

    DO - 10.3390/ph5101103

    M3 - Article

    AN - SCOPUS:84869231972

    VL - 5

    SP - 1103

    EP - 1119

    JO - Pharmaceuticals

    JF - Pharmaceuticals

    SN - 1424-8247

    IS - 10

    ER -